Researchers have created a new kind of nanoparticle that could make ultrasound-based cancer treatments more effective and safer, while also helping prevent tumors from coming back. The study ...

Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for ...